KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 1

Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?

Khairy H MORSY
Amr ZAGHLOUL
Magdy MAHMOUD
Sayfa
55–61
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further trials are required to investigate the role of EPA in the current regimens of HCV treatment that include ribavirin

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Combination therapy with peginterferon (PEG-IFN) and ribavirin (RBV) has been recommended as a standard therapy for patients with chronic hepatitis C virus (HCV).
📊
Temel Bulgular & Veri:Our aim was to evaluate the efficacy of eicosapentaenoic acid (EPA) against RBV-associated hemolytic anemia.Materials and Methods: Two hundred and forty HCV patients included in the study were randomized to either the EPA group (n=120) or non-EPA group (n=120), and they received combination therapy with or without EPA.
💡
Sonuç & Katkı:Further trials are required to investigate the role of EPA in the current regimens of HCV treatment that include ribavirin
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Combination therapy with peginterferon (PEG-IFN) and ribavirin (RBV) has been recommended as a standard therapy for patients with chronic hepatitis C virus (HCV). Our aim was to evaluate the efficacy of eicosapentaenoic acid (EPA) against RBV-associated hemolytic anemia.Materials and Methods: Two hundred and forty HCV patients included in the study were randomized to either the EPA group (n=120) or non-EPA group (n=120), and they received combination therapy with or without EPA. We compare changes in hemoglobin levels with RBV dose reduction rate in each group as well as treatment response. Results: Of 120 patients randomized to receive combination therapy with EPA, 15/86 (17.5%) patients required RBV dose reduction, whereas 71/86 (82.5%) patients did not require RBV dose reduction; in the non-EPA group, 22/80 (27.5%) patients required RBV dose reduction and 58/80 (72.5%) patients did not require RBV dose reduction. There was no significant difference between the two groups in the rates of virologic response.Conclusion: EPA can decrease the rate of RBV dose reduction and RBV-induced hemolysis during the course of combination treatment. Further trials are required to investigate the role of EPA in the current regimens of HCV treatment that include ribavirin

🔖

Bu Makaleye Atıf Yap

MORSY, K. H., ZAGHLOUL, A., MAHMOUD, M. (2016). Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 1, 55–61. https://ajindex.com/articles/409312

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
  2. Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus riba- virin: a review of its use in the management of chronic hepatitis C. Drugs 2003; 63: 701-30.
  3. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of ac- tion of ribavirin. Rev Infect Dis 1990; 12: 1132-46.
  4. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia in- duced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004. Sies H. Oxidative stress: Oxidants and antioxidants. Exp Physiol 1997; 82: 291-5.
  5. Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MM, Ou JH. Reactive oxy- gen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 2004; 39: 81-9.
  6. Singal AK, Jampana SC, Weinman SA. Antioxidant as therapeutic agents for liver disease. Liv Int 2011; Nov; 31: 1432-48. Calder PC. Polyunsaturated fatty acids and cytokine profiles: a clue to the changing prevalence of atopy? Clin Exp Allergy 2003; 33: 412-5.
  7. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflam- matory actions generated from omega-3 fatty acids via cyclooxy- genase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000; 192: 1197-204.
  8. Ide T, Okamura T, Kumashiro R, et al. A pilot study of eicosapen- taenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C. Int J Mol Med 2003; 11: 729-32.
  9. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
  10. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to riba- virin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroen- terol 2004; 39: 668-73.
  11. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differen- tial effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlip- idemic, overweight men. Circulation 2000; 102: 1264-9.
  12. Hino K, Murakami Y, Nagai A, et al. Alpha tocopherol [corrected] and ascorbic acid [corrected] attenuates the ribavirin [corrected] induced decrease in ecosapentaenoic acid in erythrocyte mem- brane in chronic hepatitis C patients. J Gastroentrol Hepatol 2006; 21: 1269-75.
  13. Roosha K, Parloop B.Omega-3